secwatch.observer — SEC 8-K summary
======================================

Issuer:     MiNK Therapeutics, Inc. (INKT)
CIK:        0001840229
Form:       8-K
Filed at:   2024-09-13T23:59:59+00:00
Accession:  0000950170-24-106345
Event type: regulatory
Sentiment:  negative
Materiality: 0.50
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

MiNK Therapeutics receives Nasdaq MVLS deficiency notice; has until March 12, 2025 to comply
--------------------------------------------------------------------------------

- Received Nasdaq letter on September 13, 2024 for failing MVLS (minimum value of listed securities) requirement.
- MVLS was below $35 million for 30 consecutive trading days, violating Nasdaq Listing Rule 5550(b)(2).
- Company has 180 calendar days, until March 12, 2025, to regain compliance.
- To comply, MVLS must be $35M or more for at least 10 consecutive trading days.
- Failure to cure may lead to delisting; company may then appeal to a Hearings Panel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840229/000095017024106345/0000950170-24-106345-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840229/000095017024106345/inkt-20240913.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-106345

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer